Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Дедков И.П., Захарычев В.Д. Первичные новообразования средостения. К.: Здоровье, 1982. 176 p.
  2. Трахтенберг А.Х. Опухоли средостения // Комбинированное и комплексное лечение больных со злокачественными опухолями / ed. Чиссов В.И. М., 1989. P. 278–290.
  3. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Vol. 21, № 2. P. прил. 2.
  4. Eralp Y. et al. Resectable Thymoma: Treatment Outcome and Prognostic Factors in the Late Adolescent and Adult Age Group // Cancer Invest. 2003. Vol. 21, № 5. P. 737–743.
  5. Wick M.R. et al. Primary mediastinal carcinoid tumors. // Am. J. Surg. Pathol. 1982. Vol. 6, № 3. P. 195–205.
  6. Морозов А.И., Сазонов А.М., Коршунов А.И. Лучевая и комплексная химиолучевая терапия злокачественных опухолей вилочковой железы после паллиативных хирургических вмешательств // Советская медицина. 1991. Vol. 7. P. 53–56.
  7. Харченко В.П., Саркисов Д.., Ветшев П.С. Болезни вилочковой железы. М.: Триада-Х, 1998. 179–83 p.
  8. Пикин О.В. et al. Опухоли средостения: сборник под ред. академика РАН, профессора А.Д. Каприна. М.: Молодая гвардия, 2019. 232 p.
  9. Сакаева Д.Д., Лазарева Д.Н. Клиническая фармакология в онкологии. М.: Медицинское информационное агентство, 2007. 336 p.
  10. Орлова Р.В. et al. Практические рекомендации по лечению анемии при злокачественных новообразованиях // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2019. Vol. 9. P. 7.
  11. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. М.: Автореф. дис. … д-ра мед. наук, 2015. 254 p.
  12. Трякин А.А., Гладков О.А., Матвеев В.Б. Практические рекомендации по лекарственному лечению герминогенных опухолей яичка // Злокачественные опухоли. 2016. Vol. 4, № спецвып.2. P. 353–366.
  13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. // J. Clin. Oncol. 1997. Vol. 15, № 2. P. 594–603.
  14. Honecker F. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. // Ann. Oncol.  Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № 8. P. 1658–1686.
  15. Пирогов А.И., Полоцкий Б.Е., Лактионов К.П. Характеристика тимом и их прогноз // Советская медицина. 1983. Vol. 12. P. 99–102.
  16. Silvestri G.A. et al. Endoscopic ultrasound with fine-needle aspiration in the Diagnosis and staging of lung cancer // Ann. Thorac. Surg. 1996. Vol. 61, № 5. P. 1441–1446.
  17. Herth F.J.F. et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes // Thorax. 2006. Vol. 61, № 9. P. 795–798.
  18. Барчук А.С., Лемехов В.Г., Клименко В.Н. Диагностические и лечебные возможности видеоторакоскопии в условиях онкологической торакальной клиники // Высокие технологии в онкологии Материалы 5-го Всероссийского съезда онкологов. 2000. Vol. 2. P. 9–11.
  19. Шевченко Ю.А. et al. Сорокалетний опыт хирургического лечения генерализованной миастении // Хирургия. 2004. Vol. 5. P. 32–38.
  20. Ветшев П.С. et al. Хирургическое лечение тимом у больных генерализованной миастенией // Хирургия. 2003. Vol. 10. P. 15–19.
  21. Ганул В.Л., Ганул А.В. О диагностике и лечении опухолей вилочковой железы // Советская медицина. 1988. Vol. 6. P. 13–17.
  22. Греджев А.Ф., Ступаченко О.Н., Кравец В.С. Хирургическое лечение новообразований вилочковой железы // Грудная хирургия. 1986. Vol. 4. P. 59–63.
  23. Kondo K. Optimal therapy for thymoma // J. Med. Investig. 2008. Vol. 55, № 1,2. P. 17–28.
  24. Boston B. Chemotherapy of invasive thymoma. // Cancer. 1976. Vol. 38, № 1. P. 49–52.
  25. Loehrer P.J. et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. // J. Clin. Oncol. American Society of Clinical Oncology, 1994. Vol. 12, № 6. P. 1164–1168.
  26. Loehrer P.J. et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. // J. Clin. Oncol. American Society of Clinical Oncology, 1997. Vol. 15, № 9. P. 3093–3099.
  27. Giaccone G. et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. // J. Clin. Oncol. Lippincott Williams and Wilkins, 1996. Vol. 14, № 3. P. 814–820.
  28. Lemma G.L. et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma // J. Clin. Oncol. 2011. Vol. 29, № 15. P. 2060–2065.
  29. Loehrer P.J. et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial // Cancer. 2001. Vol. 91, № 11. P. 2010–2015.
  30. Мачаладзе З.О. Опухоли средостения (дифференциальная диагностика и лечение). М.: Автореф. дис. … д-ра мед. наук, 2008. 506 p.
  31. Ахмедов Б.Б. Внутригрудные первичные и метастатические герминогенные опухоли (клиника, диагностика, лечение). М.: Автореф. дис. … канд. мед. наук, 2004. 144 p.
  32. Loehrer P.J. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. // J. Clin. Oncol. 1998. Vol. 16, № 7. P. 2500–2504.
  33. Тюляндин С.А., Переводчикова Н.И., Носов Д.А. Минимальные клинические рекомендации Европейского общества медицинской онкологии. М.: Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2010. 146 p.
  34. Переводчикова Н.И. Руководство по химиотерапии опухолевых заболеваний. М.: Практическая медицина, 2005. 699 p.
  35. Tryakin A., Fedyanin M., Mitin A. Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): Is there a place for adjunctive surgery? // J Clin Oncol. 2012. Vol. 30, № 15, suppl. P. 15029.
  36. Давыдов М.М., Полоцкий Б.Е., Мачаладзе З.О. Мезенхимальные опухоли средостения: пособие для врачей. М.: Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2015.
  37. Ткачев С.И. et al. Консервативное лечение больных агрессивным фиброматозом // Вестник РОНЦ РАМН им. Блохина РАМН. 2004. Vol. 3. P. 61–66.
  38. Бирюков Ю.В., Чарнецкий Р.И., Годжелло Э.А. Сосудистые новообразования средостения // Хирургия. 1991. Vol. 4. P. 3–7.
  39. Shenoy S.S. et al. Mediastinal lymphangioma. // J. Surg. Oncol. 1978. Vol. 10, № 6. P. 523–528.
  40. Cakir E. et al. Primary mediastinal haemangiopericytoma--an unusual cause of massive haemoptysis in a young woman. // Acta Chir. Belg. 2010. Vol. 110, № 2. P. 235–237.
  41. Мачаладзе З.О. et al. Опухоли мягких тканей средостения // Грудная и сердечно-сосудистая хирургия. 2008. Vol. 1. P. 59–65.
  42. Antic T., Staerkel G. Mediastinal epithelioid hemangioendothelioma metastatic to lymph nodes and pleural fluid: report of a case. // Diagn. Cytopathol. 2010. Vol. 38, № 2. P. 113–116.
  43. Вишневский А.А., Адамян А.А. Хирургия средостения. М.: Медицина, 1977. 138–194 p.
  44. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. // Am. J. Phys. Med. Rehabil. 2013. Vol. 92, № 8. P. 715–727.
  45. Nilsson H. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. // BMJ Open. 2016. Vol. 6, № 1. P. e007997.
  46. Eustache J. et al. Enhanced recovery after pulmonary surgery // J. Thorac. Dis. 2018. Vol. 10, № S32. P. S3755–S3755.
  47. Medbery R.L., Fernandez F.G., Khullar O. V. ERAS and patient reported outcomes in thoracic surgery: a review of current data. // J. Thorac. Dis. AME Publications, 2019. Vol. 11, № Suppl 7. P. S976–S986.
  48. Field T. Massage therapy research review // Complement. Ther. Clin. Pract. 2016. Vol. 24. P. 19–31.
  49. Oren R. et al. Musculoskeletal Cancer Surgery / ed. Malawer. Springer, 2013. 583–593 p.
  50. Segal R. et al. Exercise for people with cancer: a systematic review. // Curr. Oncol. 2017. Vol. 24, № 4. P. e290–e315.
  51. Boyd C. et al. The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. // Pain Med. 2016. Vol. 17, № 8. P. 1553–1568.
  52. Stout N.L. et al. A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017). // PM R. 2017. Vol. 9, № 9S2. P. S347–S384.
  53. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. // Acta Haematol. 2012. Vol. 127, № 3. P. 156–164.
  54. Bland K.A. et al. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. // Crit. Rev. Oncol. Hematol. 2019. Vol. 136. P. 79–85.
  55. Mustian K.M. et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. // JAMA Oncol. 2017. Vol. 3, № 7. P. 961–968.
  56. Kinkead B. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. // Cancer. 2018. Vol. 124, № 3. P. 546–554.
  57. Streckmann F. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. // Sports Med. 2014. Vol. 44, № 9. P. 1289–1304.
  58. Rick O. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. // Bioelectromagnetics. 2017. Vol. 38, № 2. P. 85–94.
  59. Kılınç M. et al. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. // J. Rehabil. Med. 2014. Vol. 46, № 5. P. 454–460.
  60. Oberoi S. et al. Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta-Analysis // PLoS One / ed. Hamblin M. 2014. Vol. 9, № 9. P. e107418.
  61. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy // J. Thorac. Dis. 2018. Vol. 10, № S35. P. S4391–S4399.
  62. Kessels E., Husson O., Van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis // Neuropsychiatr. Dis. Treat. 2018. Vol. Volume 14. P. 479–494.
  63. Rief H. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. // BMC Cancer. 2014. Vol. 14, № 1. P. 67.
  64. Bensadoun R.-J., Nair R.G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy // Photomed. Laser Surg. 2015. Vol. 33, № 10. P. 487–491.
  65. Temoshok L. Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. // Soc. Sci. Med. 1985. Vol. 20, № 8. P. 833–840.
  66. Devine D. et al. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. // Psychooncology. 2003. Vol. 12, № 5. P. 453–462.
  67. Folkman S. et al. Appraisal, coping, health status, and psychological symptoms. // J. Pers. Soc. Psychol. 1986. Vol. 50, № 3. P. 571–579.
  68. Fawzy F.I. et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. // Arch. Gen. Psychiatry. 1990. Vol. 47, № 8. P. 720–725.
  69. Honnings J., Gaissert H.A. Tumors of the Trachea // ESTS Textbook of Thoracic Surgery / ed. Kuzdzal J. Cracow: Medycyna Praktyczna, 2014. P. 359–373.
  70. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET C.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. - PubMed - NCBI // Am J Clin Oncol. 1982. Vol. 5, № 6. P. 649–655.
  71. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer // Evaluation of chemotherapeutic agents / ed. MacLeod C. New York: Columbia University Press, 1949. P. 191–205.
  72. Eisenhauer E.A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) // Eur. J. Cancer. 2009. Vol. 45, № 2. P. 228–247.
  73. Hawker G.A. et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). // Arthritis Care Res. (Hoboken). 2011. Vol. 63 Suppl 11, № S11. P. S240-52.
  74. Ohnhaus E.E., Adler R. Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. // Pain. 1975. Vol. 1, № 4. P. 379–384.
  75. Nicholson AG, Detterbeck FC, Marino M et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9: s73-s80.
  76. Kondo K, Van Schil P, Detterbeck FC et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9: s81-s87.
  77. Detterbeck FC, Stratton K, Giroux D et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9: s65-s72.
  78. Дидаев С.И. Антитела к аутоантигенным мишеням при миастении и их значение в клинической практике. Нервно-мышечные болезни. 2014;2:6-15
  79. Санадзе А.Г. Миастения и миастенические синдромы: руководство. М.: Литтера, 2012. 256 с.
  80. Lindstrom J. Antibody specificities in autoimmune myasthenia gravis. Neuromuscular Diseases. N. Y., 1984. P. 481–495.
  81. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009;115:5413-5420
  82. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 2009;87:1641-1647.
  83. Basse C, Thureau S, Bota S, et al. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol 2017;12:1715-1722.
  84. Tateishi Y, Horita N, Namkoong H, et al. Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients. J Thorac Oncol 2021;16:677-685.
  85. Hamaji M, Shah RM, Ali SO, et al. A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma. Ann Thorac Surg 2017;103:1668-1675.
  86. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010;76:440-445.
  87. Ruffini E, et al. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. Eur J Cardiothorac Surg 2019;55:601-609.
  88. Litvak AM, Woo K, Hayes S, et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol 2014;9:1810-1815.
  89. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94:3115-3119.
  90. Ahmad U, Yao X, Detterbeck F, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg 2015;149:95-100, 101.e101-102.
  91. Mao Y, Wu S. Treatment and survival analyses of completely resected thymic carcinoma patients. Onco Targets Ther 2015;8:2503-2507.
  92. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.
  93. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30-33.
  94. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010;21:1168-1172.
  95. Palmieri G, Buonerba C, Ottaviano M, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol 2014;10:2141- 2147.
  96. Gbolahan OB, Porter RF, Salter JT, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol 2018;13:1940- 1948.
  97. Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol. 2016;21(3):531-8.
  98. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004;22:293-299.
  99. Zucali PA, De Pas TM, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2018;36:342-349.
  100. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19:347-355.
  101. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol 2019;37:2162- 2170.
  102. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16:177-186.
  103. Клинический алгоритм диагностикии и лечения опухолей средостения / А. Б. Рябов, О. В. Пикин, О. А. Александров [и др.] // Хирургия. Журнал им. Н.И. Пирогова. – 2022. – № 5. – С. 43-51. – DOI 10.17116/hirurgia202205143. – EDN IJMOEC]
  104. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999;81:841-5. 
  105. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543-9. 
  106. Agatsuma T, Koizumi T, Kanda S, et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 2011;6:2130-4.
  107. Yoh K, Goto K, Ishii G, et al. Weekly Chemotherapy with Cisplatin, Vincristine, Doxorubicin, and Etoposide Is an Effective Treatment for Advanced Thymic Carcinoma. Cancer 2003;98:926-31.
  108. Bluthgen MV, Boutros C, Fayard F, et al. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer 2016;99:111-6.
  109. Yoh K, Goto K, Ishii G, et al. Weekly Chemotherapy with Cisplatin, Vincristine, Doxorubicin, and Etoposide Is an Effective Treatment for Advanced Thymic Carcinoma. Cancer 2003;98:926-31.
  110. Grassin F, Paleiron N, André M, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 2010;5:893-7.
  111. Antonarelli G, Corti C, Zucali P.A., Perrino M, Manglaviti S, Lo Russo G, Varano G.M et all. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group. Eur J Cancer. 2022; 174: 31-36
  112. Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol. 2016;21(3):531-8

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу